PILs: all harms and no benefits, Irish College of GPs end pharma funding, Ryeqo for fibroids

In this podcast recorded in early December, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2025 issue of DTB. They provide an overview of the editorial that questions whether it is time for the medicine Patient Information Leaflet (PIL) to include information on the impact of a medicine on clinical outcomes - . They talk about a recent announcement from the Irish College of GPs that it is phasing out sponsorship from pharmaceutical companies as evidence suggests that ‘engagement between pharmaceutical companies and prescribers is associated with inappropriately increased prescribing rates, lower prescribing quality and increased prescription costs’ - The main article provides an overview of Ryeqo (relugolix, estradiol and norethisterone acetate) for the treatment of moderate to severe symptoms of uterine fibroids - . The podcast ends with a farewell to James, who is stepping down as Editor-in-Chief after more than 12 years. James reflects on his time as a doctor, GP and Editor of DTB. Other links: Is ASCOT all it's cracked up to be? Don't lose your head over ASCOT

You can listen to PILs: all harms and no benefits, Irish College of GPs end pharma funding, Ryeqo for fibroids online on Radio and Podcast. Open the player on this page to stream the available audio.

PILs: all harms and no benefits, Irish College of GPs end pharma funding, Ryeqo for fibroids is an episode from DTB podcast by BMJ Group.

This episode is 29:00 long.

This episode was published on Dec 30, 2024.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from DTB podcast when more episodes are available from the podcast feed.